Please use this identifier to cite or link to this item: https://dspace.iiti.ac.in/handle/123456789/3832
Title: SILAC-based quantitative MS approach reveals Withaferin A regulated proteins in prostate cancer
Authors: Kumar, Ramesh
Nayak, Debasis
Somasekharan, Syam Prakash
Keywords: 60S ribosomal protein L10;aars2 protein;aimp1 protein;aldh1b1 protein;ascf3 protein;asparagine linked oligosaccharide;ataxin 2;atxn2l protein;calm protein;caprin1 protein;cdc5l protein;cdk1 protein;chdh protein;chmp1b protein;coa3 protein;commd3 protein;cox7a2 protein;cpox protein;cpsf6 protein;cyb5a protein;cyb5b protein;ddx1 protein;ddx3x protein;ddx42 protein;ddx47 protein;ddx5 protein;dnaja1 protein;dnajb1 protein;dnajc7 protein;drg1 protein;dstn protein;dual specificity phosphatase 3;dyskerin;eif2s3 protein;eif3b protein;eif4a3 protein;eif4g1 protein;ELAV like protein 1;eral1 protein;erlin2 protein;ero1a protein;fbl protein;fkbp3 protein;fxr2 protein;g3bp1 protein;gbe1 protein;gfm2 protein;gpd2 protein;hars1 protein;hnrnpc protein;hnrnpu protein;hsp90aa1 protein;hspa1a protein;hspa4 protein;hsph1 protein;jpt2 protein;kpna2 protein;larp4 protein;lemd2 protein;lmna protein;lmnb1 protein;lmnb2 protein;man2b1 protein;mapk3 protein;mgat2 protein;minichromosome maintenance protein 4;minichromosome maintenance protein 5;mogs protein;mrpl11 protein;mrpl12 protein;mrpl15 protein;mrpl16 protein;mrpl23 protein;mrpl41 protein;mrpl44 protein;mrps12 protein;mrps16 protein;mrps23 protein;mtap protein;mthfd1 protein;mybbp1a protein;nbas protein;ndufab1 protein;ndufaf1 protein;nt5c2 protein;nucleoporin 98;nudt21 protein;nup153 protein;nup37 protein;nup54 protein;p21 activated kinase 2;pabn1 protein;pabpn1 protein;paf1 protein;pcyox1l protein;pdcd4 protein;pde12 protein;pdha1 protein;pgls protein;picalm protein;pitpnb protein;pold1 protein;ppp2r5e protein;prim2 protein;prmt5 protein;protein;prpf19 protein;prpsap1 protein;psma4 protein;psmd10 protein;ptcd3 protein;ptges3 protein;rad23a protein;rad23b protein;reactive oxygen metabolite;RNA binding protein FUS;rnf40 protein;rpl12 protein;rpl13a protein;rpl14 protein;rpl21 protein;rpl26 protein;rpl31 protein;rpl35 protein;rpl35a protein;rpl36al protein;rpl6 protein;rpl7a protein;rps13 protein;rps15a protein;rps16 protein;rps19 protein;rps24 protein;rps25 protein;rps29 protein;rps3a protein;rps4x protein;rps6 protein;rps7 protein;scamp4 protein;sf3a2 protein;sf3b6 protein;sfpq protein;sgta protein;smc2 protein;snrpa1 protein;snrpd1 protein;srrm2 protein;srsf6 protein;srsf7 protein;stromal interaction molecule 1;tardbp protein;tcof1 protein;tomm34 protein;txn protein;ube2l3 protein;ufc1 protein;unclassified drug;vbp1 protein;vps4b protein;withaferin A;Y box binding protein 1;ythdf2 protein;DNA helicase;G3BP1 protein, human;poly ADP ribose binding protein;RNA helicase;RNA recognition motif protein;withaferin A;withanolide;22Rv1 cell line;amino acid metabolism;apoptosis;Article;carbohydrate metabolism;castration-resistant prostate cancer cell line;cell culture;cell cycle;cell damage;cell growth;cell lysate;cell proliferation;cell protection;cell survival;chromatin assembly and disassembly;citric acid cycle;controlled study;DNA repair;down regulation;DU145 cell line;endocytosis;endoplasmic reticulum stress;fatty acid synthesis;gene expression;gene knockdown;gluconeogenesis;Golgi complex;heat shock response;heat tolerance;immunofluorescence microscopy;isotope labeling;lipid metabolism;liquid chromatography-mass spectrometry;LNCaP cell line;mass spectrometry;metabolic rate;mitochondrial gene;nucleocytoplasmic transport;nucleotide excision repair;nucleotide metabolism;ontology;oxidative stress;physiological stress;prostate cancer;protein analysis;protein expression;protein fingerprinting;protein folding;protein synthesis;proteomics;ribosome;RNA metabolism;RNA splicing;RNA translation;SILAC labeling;translation elongation;translation initiation;ubiquitination;upregulation;Western blotting;human;male;prostate tumor;proteomics;DNA Helicases;Humans;Male;Poly-ADP-Ribose Binding Proteins;Prostatic Neoplasms;Proteomics;RNA Helicases;RNA Recognition Motif Proteins;Withanolides
Issue Date: 2021
Publisher: Elsevier B.V.
Citation: Kumar, R., Nayak, D., & Somasekharan, S. P. (2021). SILAC-based quantitative MS approach reveals withaferin A regulated proteins in prostate cancer. Journal of Proteomics, 247 doi:10.1016/j.jprot.2021.104334
Abstract: Withaferin A (WA) is a steroidal lactone extracted from Withania somnifera, commonly known as Ashwagandha. WA has several therapeutic benefits. The current study aims to identify proteins that are potentially regulated by WA in prostate cancer (PCA) cells. We used a SILAC-based proteomic approach to analyze the expression of proteins in response to WA treatment at 4 h and 24 h time points in three PCA cell lines: 22Rv1, DU-145, and LNCaP. Ontology analysis suggested that prolonged treatment with WA upregulated the expression of proteins involved in stress-response pathways. Treatment with WA increased oxidative stress, reduced global mRNA translation, and elevated the expression of cytoprotective stress granule (SG) protein G3BP1. WA treatment also enhanced the formation of SGs. The elevated expression of G3BP1 and the formation of SGs might constitute a mechanism of cytoprotection in PCA cells. Knockdown of G3BP1 blocked SG formation and enhanced the efficacy of WA to reduce PCA cell survival. Significance: Withaferin A, a steroidal lactone, extracted from Withania somnifera is a promising anti-cancer drug. Using a SILAC-based quantitative proteomic approach, we identified proteins changed by WA-treatment at 4 h and 24 h in three prostate cancer (PCA) cell lines. WA-treatment induced the expression of proteins involved in apoptosis and reduced the expression of proteins involved in cell growth at 4 h. WA-treatment for 24 h enhanced the expression of proteins involved in stress response pathways. WA-treated cells exhibited increased oxidative stress, reduced mRNA translation and enhanced SG formation. PCA is characterized by higher metabolic rate and increased oxidative stress. PCA with a higher stress tolerance can effectively adapt to anti-cancer treatment stress, leading to drug resistance and cellular protection. Enhancing the level of oxidative stress along with inhibition of corresponding cytoprotective stress response pathways is a feasible option to prevent PCA from getting adapted to treatment stress. WA-treatment induced oxidative stress, in combination with blocking SGs by G3BP1 targeting, offers a therapeutic strategy to reduce PCA cell survival. © 2021 Elsevier B.V.
URI: https://doi.org/10.1016/j.jprot.2021.104334
https://dspace.iiti.ac.in/handle/123456789/3832
ISSN: 1874-3919
Type of Material: Journal Article
Appears in Collections:Department of Biosciences and Biomedical Engineering

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetric Badge: